Hadden Advances in Immunopharmacology

Proceeding of the Fourth International Conference on Immunopharmacology, Osaka, Japan, 16-19 May 1988
1. Auflage 2013
ISBN: 978-1-4832-8682-2
Verlag: Elsevier Science & Techn.
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, 337 Seiten, Web PDF

The Fourth International Conference on Immunopharmacology took place in Osaka, Japan, May 1988. It was attended by over 900 participants from a variety of fields, illustrating the broad interest and wide-ranging applications of the subject. This Proceedings volume provides a comprehensive record of the Conference and is organized according to the sectional headings employed at the meeting. The topics covered include basic and clinical immunology, and preclinical and clinical aspects of immunopharmacology. The material presented is referenced and indexed throughout, and illustrated with photographs, diagrams and tables.

Autoren/Hrsg.

Hadden, J. W.

Inhaltsverzeichnis

1;Front Cover
;1
2;Advances in Immunopharmacology 4;4
3;Copyright Page;5
4;Table of Contents;6
5;Part I: Secondary immunodeficiency and its Therapy;10
5.1;Chapter 1. Introduction and Overview on AIDS;12
5.1.1;ACKNOWLEDGEMENTS;17
5.1.2;REFERENCES;18
5.2;Chapter 2. AIDS Vaccine Development—1988;20
5.2.1;ABSTRACT;20
5.2.2;KEYWORDS;20
5.2.3;INTRODUCTION;20
5.2.4;ACKNOWLEDGEMENT;26
5.2.5;REFERENCES;26
5.3;Chapter 3. Current Immunotherapeutic Efforts and Future Prospects in Human HIV Disease;28
5.3.1;ABSTRACT;28
5.3.2;KEY WORDS;28
5.3.3;REFERENCES;36
5.4;Chapter 4. Experience in the Immunotoxicity Testing of Recombinant Cytokines;38
5.4.1;KEY WORDS;38
5.4.2;INTRODUCTION;38
5.4.3;TOXICITY OF INTERFERONS;38
5.4.4;TOXICITY OF INTERLEUKIN-2;40
5.4.5;CONCLUSIONS;46
5.4.6;ACKNOWLEDGEMENTS;47
5.4.7;REFERENCES;47
6;Part II: Immunopharmacology of Neuroendocrine Interaction;48
6.1;Chapter 5. Overview on Neuroimmunomodulation anda Possible Role for Serotonergic System;50
6.1.1;ABSTRACT;50
6.1.2;KEYWORDS;50
6.1.3;REFERENCES;53
6.2;Chapter 6. A Molecular Basis for Bidirectional Communication between the Neuroendocrine and Immune Systems;56
6.2.1;KEYWORDS;56
6.2.2;COMMUNICATION BETWEEN THE NEUROENDOCRINE AND IMMUNE SYSTEMS;56
6.2.3;PRO-OPIOMELANOCORTIN (POMC) PRODUCTION BY LEUKOCYTES;57
6.2.4;OTHER NEUROENDOCRINE HORMONES PRODUCED BY LEUKOCYTES;58
6.2.5;COHNON MOLECULAR HECHANISNS;59
6.2.6;IMPLICATIONS;60
6.2.7;ACKNOWLEDGMENTS;61
6.2.8;REFERENCES;61
6.3;Chapter 7. Enhancement of Mammalian Sleep by Immune Modulators;64
6.3.1;ABSTRACT;64
6.3.2;KEYWORDS;64
6.3.3;INTRODUCTION;64
6.3.4;CONCLUSION;70
6.3.5;ACKNOWLEDGMENTS;71
6.3.6;REFERENCES;71
6.4;Chapter 8. Physiological Roles of Histamine Ha-Receptors;74
6.4.1;ABSTRACT;74
6.4.2;KEYWORDS;74
6.4.3;INTRODUCTION;74
6.4.4;ALPHA METHYLHISTAMINE AM) THIOPERAMIDE : TWO POTENT AM) SELECTIVE LIGAMDS;75
6.4.5;IN VIVO ACTION;77
6.4.6;ASSAY AND VISUALIZATION OF H3-RECEPTORS;78
6.4.7;CONCLUSIONS;79
6.4.8;REFERENCES;79
7;Part III: ímmunoregulatory Molecules, Receptors and their Immunopharmacological Implications;80
7.1;Chapter 9. Cell-Cell Contact- and Cytokine-controUed . Lymphocyte Responses and their Potential Influences in Hematopoiesis;82
7.1.1;KEYWORDS;82
7.1.2;INTRODUCTION;82
7.1.3;CYTOKINE PRODUCTION BY THE ANTIGEN-SPECIFIC, MHC-RESTRICTED INTERACTIONOF HELPER . CELLS WITH ACCESSORY CELLS.;83
7.1.4;THE ACTIONS OF CYTOKINES ON RESTING . CELLS;83
7.1.5;EXCITATION OF . CELLS FROM THE RESTING STATE;83
7.1.6;PROGRESSION THROUGH THE CELL CYCLE;83
7.1.7;RECEPTORS FOR IL-5;84
7.1.8;THE MULTIPLE ACTIONS OF MULTIPLE CYTOKINES;88
7.1.9;ACKNOWLEDGEMENTS;88
7.1.10;REFERENCES;88
7.2;Chapter 10. The Colony Stimulating Factors: Discovery to Clinical Applications;90
7.2.1;ABSTRACT;90
7.2.2;KEY WORDS;90
7.2.3;DISCOVERY OF THE COLONY STIMULATING FACTORS;90
7.2.4;CHEMICAL NATURE AND GENETIC ARRANGEMENT OF THE CSF's;91
7.2.5;FUNCTIONAL ACTIONS OF THE CSF's;92
7.2.6;RESPONSES IN VIVO TO THE CSF's;92
7.2.7;ROLE OF THE CSF's IN RESISTANCE TO INFECTIONS;93
7.2.8;RESPONSES IN MAN TO THE INJECTION OF CSF;94
7.2.9;POSSIBLE TOXIC EFFECTS OF THE CSF's;94
7.2.10;REFERENCES;95
7.3;Chapter 11. Characterization of the Mouse Interleukin 3 Receptor System;96
7.3.1;SUMMARY;96
7.3.2;INTRODUCTION;96
7.3.3;SIGNAL TRANSDUCTION PATHWAY OF I L - 3;97
7.3.4;RECEPTOR EXCHANGE EXPERIMENTS;99
7.3.5;STRUCTURE OF THE IL-3 RECEPTOR;100
7.3.6;MONOCLONAL ANTIBODY AGAINST THE I L - 3 RECEPTOR;101
7.3.7;REFERENCES;101
7.4;Chapter 12. Interleukin-2 Receptor Targeted Immunosuppressive Therapy with Anti-Interleukin-2 Receptor Monoclonal Antibodies Directed against the L-Chain of the Interleukin-2 Receptor: Studies on Selectivity and Mode of Action;104
7.4.1;INTRODUCTION;104
7.4.2;CONCLUSION;113
7.4.3;REFERENCES;113
7.5;Chapter 13. Efficacy of Low-dose Cyclophosphamide and Interleukiii-2 in Melanoma;114
7.5.1;ABSTRACT;114
7.5.2;KEY WORDS;114
7.5.3;INTRODUCTION;115
7.5.4;PATIENTS;116
7.5.5;REGIMEN;116
7.5.6;IMMUNOLOGICAL STUDIES;118
7.5.7;RESULTS;118
7.5.8;DISCUSSION;124
7.5.9;ADDENDUM;126
7.5.10;REFERENCES;127
7.6;Chapter 14. Anti-idiotype Modeled Peptides with Biologic Activity;128
7.6.1;ABSTRACT;128
7.6.2;KEYWORDS;128
7.6.3;INTRODUCTION;128
7.6.4;MATERIALS AND METHODS;129
7.6.5;RESULTS;130
7.6.6;REFERENCES;135
7.7;Chapter 15. Pharmacokinetics and Organ Targeting of Monoclonal Antibodies;136
7.7.1;ABSTRACT;136
7.7.2;KEYWORDS;136
7.7.3;INTRODUCTION;136
7.7.4;REFERENCES;138
8;Part IV: Recent Advances in Vaccine Development;140
8.1;Chapter 16. Modulation of the Immunogenic Characters of Protective Epitopes in Synthetic Vaccines;142
8.1.1;ABSTRACT;142
8.1.2;KEYWORDS;142
8.1.3;INTRODUCTION;142
8.1.4;FROM CONVENTIONAL TO SYNTHETIC VACCINES.;143
8.1.5;SYNTHETIC ANTI-MALARIA VACCINES;144
8.1.6;IMMUNOGENIC PROPERTIES OF (NANP)8 HOMOPOLYMERIZED OR CONJUGATED TO TETANUS TOXOID AFTER ADMINISTRATION TO DIFFERENT STRAINS OF MICE.;145
8.1.7;SEQUENCE OF THE PEPTIDES CONTAINED IN THE POLYVALENT VACCINE.;146
8.1.8;SPECIFICITY OF THE ANTIBODY AND . CELL PROLIFERATIVE RESPONSES INDUCED BY ASYNTHETIC POLYVALENT VACCINE.;147
8.1.9;EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS (EAE).;147
8.1.10;1-EAE INDUCTION.;148
8.1.11;2-EAE PREVENTION.;148
8.1.12;CONCLUDING REMARKS;150
8.1.13;REFERENCES;150
8.2;Chapter 17. Current Status of Malaria Vaccines: The Need for Safe and Effective Adjuvants;152
8.2.1;ABSTRACT;152
8.2.2;KEYWORDS;152
8.2.3;INTRODUCTION;152
8.2.4;SPOROZOITE VACCINES;152
8.2.5;ASEXUAL BLOOD-STAGE VACCINES;153
8.2.6;ADJUVANTS;154
8.2.7;CONCLUSION;155
8.2.8;REFERENCES;155
8.3;Chapter 18. Immunoadjuvants for Vaccine;158
8.3.1;ABSTRACT;158
8.3.2;KEYWORDS;158
8.3.3;INTRODUCTION;158
8.3.4;ACKNOWLEDGMENTS;165
8.3.5;REFERENCES;165
9;Part V: Immunopharmacology of Model Cytokine, IL-6 (BSF2/IFNß2];168
9.1;Chapter 19. Interleukin 6 and its Receptor: Pathological Role in Autoimmunity and Lymphoid Malignancy;170
9.1.1;ABSTRACT;170
9.1.2;KEYWORDS;170
9.1.3;INTRODUCTION;170
9.1.4;STRUCTURE OF IL-6 AND ITS GENE;171
9.1.5;PRODUCTION OF I L - 6 .;172
9.1.6;I L - 6 RECEPTOR IS AN IMMUNOGLOBUL IN SUPERFAMILY.;172
9.1.7;ESSENTIAL ROLE OF IL-6 IN THE ANTIBODY FORMATION.;173
9.1.8;I L - 6 AND AUTOIMMUNE DISEASES;174
9.1.9;I L - 6 IS AN AUTOCRINE GROWTH FACTOR FOR MULTIPLE MYELOMAS.;175
9.1.10;CONCLUSION.;176
9.1.11;ACKNOWLEDGEMENTS;176
9.1.12;REFERENCES;176
9.2;Chapter 20. The Hybridoma/Plasmacytoma GrowthFactor (HPGF) Activity of IL-6. Stimulationof its Secretion by Different Inducers inVarious Cell Types;178
9.2.1;KEYWORDS;178
9.2.2;INTRODUCTION;178
9.2.3;MATERIALS AND METHODS;178
9.2.4;RESULTS AND DISCUSSION;179
9.2.5;CONCLUSION;182
9.2.6;ACKNOWLEDGMENT;182
9.2.7;REFERENCES;182
9.3;Chapter 21. Interferon-type and Other Activities ofIFN-ß-2/BSF-2/HSF;184
9.3.1;ABSTRACT;184
9.3.2;INTRODUCTION;184
9.3.3;RESULTS;184
9.3.4;DISCUSSION;190
9.3.5;ACNCWLEDGEMENTS;192
9.3.6;REEERENCES;192
9.4;Chapter 22. Interleukin-6: Biological Function and Regulation of the Gene Expression in Vitroand in Vivo;194
9.4.1;INTRODUCTION;194
9.4.2;PRODUCTION OF IL6;195
9.4.3;INDUCTION OF IL6 IN VITRO;195
9.4.4;INDUCTION OF IL6 IN VIVO;196
9.4.5;CONCLUDING REMARKS;197
9.4.6;ACKNOWLEDGEMENTS;197
9.4.7;REFERENCES;198
9.5;Chapter 23. Interleukin-6 is the Major Regulator of Acute Phase Protein Synthesis in Rat andMan;200
9.5.1;ABSTRACT;200
9.5.2;KEYWORDS;200
9.5.3;INTRODUCTION;200
9.5.4;MATERIALS AND METHODS;201
9.5.5;RESULTS AND DISCUSSION;201
9.5.6;CONCLUSION;209
9.5.7;ACKNOWLEDGEMENTS;209
9.5.8;REFERENCES;210
10;Part VI: Transmembrane Signalling and Chemical Mediators;212
10.1;Chapter 24. The Role of Kinase Activation and Gene Expression in the Action of Interleukin 2;214
10.1.1;ABSTRACT;214
10.1.2;KEYWORDS;214
10.1.3;INTRODUCTION;214
10.1.4;RESULTS AND DISCUSSION;215
10.1.5;ACKNOWLEDGEMENTS;218
10.1.6;REFERENCES;218
10.2;Chapter 25. Transmembrane Events in Mast Cell Histamine Release;220
10.2.1;ABSTRACT;220
10.2.2;KEY WORDS;220
10.2.3;INTRODUCTION;220
10.2.4;ACKNOWLEDGEMENT;226
10.2.5;REFERENCES;226
10.3;Chapter 26. An Approach to the Mode of Action of Lipocortins;228
10.3.1;Abstract;228
10.3.2;Key words;228
10.3.3;Introduction;228
10.3.4;Lipocortins are constitutive proteins;229
10.3.5;Purification, regulation and sequence of lipocortins;229
10.3.6;Mode of action of lipocortins;229
10.3.7;Pharmacological aspects;230
10.3.8;Conclusion;230
10.3.9;Acknowledgments;230
10.3.10;References;230
10.4;Chapter 27. Protein Kinase C and Signal Transductionin . Lymphocytes;232
10.4.1;ABSTRACT;232
10.4.2;KEYWORDS;232
10.4.3;INTRODUCTION;232
10.4.4;MATERIALS AND METHODS;234
10.4.5;RESULTS;235
10.4.6;DISCUSSION;236
10.4.7;ACKNOWLEDGMENTS;238
10.4.8;REFERENCES;238
10.5;Chapter 28. Regulation of Human Eosinophil Phenotype;240
10.5.1;ABSTRACT;240
10.5.2;KEYWORDS;240
10.5.3;INTRODUCTION;240
10.5.4;FUNCTION OF EOSINOPHILS;240
10.5.5;HETEROGENEITY OF EOSINOPHILS;241
10.5.6;REGULATION OF EOSINOPHIL PHENOTYPE;242
10.5.7;FUTURE CONSIDERATIONS;244
10.5.8;REFERENCES;245
11;Part 7: Workshop Sessions;248
11.1;Chapter 29. Bacteria and Natural Products asImmunomodulators (II);250
11.2;Chapter 20. Bacteria and Natural Products asImmunomodulators (III);254
11.3;Chapter 21. Glucans and Immunomodifiers (I);260
11.4;Chapter 22. Glucans and Immunomodifiers (II);264
11.5;Chapter 23. Synthetic Immunomodifiers (I);268
11.6;Chapter 24. Synthetic Immunomodifiers (II);272
11.7;Chapter 25. Lymphokines and Monokines (I);276
11.8;Chapter 26. Lymphokines and Monokines (II);278
11.9;Chapter 27. Thymic Hormones;282
11.9.1;1. Thymosin;282
11.9.2;2. Thymomodulin;284
11.9.3;3. Thymolymphotropin;284
11.10;Chapter 28. Effector Functions of Cytokines in Cancer;286
11.11;Chapter 29. Clinical Applications of Cytokines;290
11.12;Chapter 30. Summary MDP and Derivatives;294
11.12.1;INTRODUCTION;294
11.12.2;MDPs AS ADJUVANTS IN VACCINES;294
11.12.3;MDPs FOR STIMULATION OF NON-SPECIFIC IMMUNITY AGAINST INFECTION;295
11.12.4;MACROPHAGE ACTIVATION BY MDPs FOR THE INDUCTION OF TUMORICIAL ACTIVITIES;295
11.12.5;IMMUNOPHARMACOLOGICAL MECHANISMS OF MDPs;295
11.12.6;SUMMARY;296
11.13;Chapter 31. Allergy and Antiallergies;298
11.14;Chapter 32. Pharmacology of Immunocytes;300
11.15;Chapter 33. Immunotoxicology;304
11.16;Chapter 34. Novel Aspects and Approaches inImmunomanipulation;308
11.17;Chapter 35. Immune Manipulation in Infectious Diseases;310
11.18;Chapter 36. Novel Vaccines;312
11.19;Chapter 37. Immunosuppressive Agents (I)Deoxyspergualin and Other InterestingAgents;316
11.19.1;REFERENCES;319
11.20;Chapter 38. Immunosuppressive Agents (II);320
11.20.1;REFERENCES;323
11.21;Chapter 39. Endotoxins;324
11.22;Chapter 40. Drug Delivery Systems Including Liposomesas Carriers;326
11.23;Chapter 41. Immunomodulatory Effects of TraditionalMedicines;330
11.23.1;IMMUNOPOTENTIATION EFFECTS OF SOME TRADITIONAL MEDICINES;330
11.23.2;IMMUNOSUPPRESSIVE EFFECT OF SOME TRADITIONAL MEDICINES;332
12;Author Index;334
13;Subject Index;336